Hoth Therapeutics Shares Rise 14% After FDA Clearance for HT-001 Trial Amendments
By Chris Wack
Hoth Therapeutics shares were up 14% to $1.47 after the company received U.S. Food and Drug Administration clearance to implement a number of protocol amendments to its ongoing clinical trial for HT-001.
The stock hit its 52-week low of 99 cents on Nov. 15, and is down 74% in the past 12 months.
The biopharmaceutical company's HT-001 is being developed as a potential treatment for cancer patients undergoing treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors.
The trial is being conducted under Hoth's open Investigational New Drug Application for HT-001.
The goal of the study is to determine the minimum efficacious dose strength for further investigation. The dose effect, together with the application site safety assessments, and therapeutic effects based on the primary and secondary endpoints will be evaluated.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 18, 2024 11:11 ET (16:11 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Apple Earnings: iPhone Growth Forecasts Drive Change in Fair Value
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted